Endocannabinoid system in neurodegenerative disorders

Journal of Neurochemistry

Volumn 142, Issue 5, 2017, Pages 624-648

  Basavarajappa, Balapal S ^a,b,c,d   Shivakumar, Madhu ^a   Joshi, Vikram ^a   Subbanna, Shivakumar ^a  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c Columbia University ^*  (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; CB1 receptors; Huntington's disease; Loss of neurons; motor and memory behavior; Parkinson's disease

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; ENDOCANNABINOID; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AFFECTING AGENT;

ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; DEGENERATIVE DISEASE; HUMAN; HUNTINGTON CHOREA; INTRACELLULAR SIGNALING; MOLECULAR PATHOLOGY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; ANIMAL; METABOLISM; NEURODEGENERATIVE DISEASES;

ANIMALS; CANNABINOID RECEPTOR MODULATORS; ENDOCANNABINOIDS; HUMANS; NEURODEGENERATIVE DISEASES; RECEPTORS, CANNABINOID;

EID: 85021708508     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.14098     Document Type: Review

References (255)

1. Ahmad R., Goffin K., Van den Stock J. et al. (2014) In vivo type 1 cannabinoid receptor availability in Alzheimer's disease. Eur. Neuropsychopharmacol. 24, 242–250.
2. Ahmad R., Postnov A., Bormans G., Versijpt J., Vandenbulcke M. and Van Laere K. (2016) Decreased in vivo availability of the cannabinoid type 2 receptor in Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 43, 2219–2227.
3. Allen K. L., Waldvogel H. J., Glass M. and Faull R. L. (2009) Cannabinoid (CB(1)), GABA(A) and GABA(B) receptor subunit changes in the globus pallidus in Huntington's disease. J. Chem. Neuroanat. 37, 266–281.
4. Arrasate M. and Finkbeiner S. (2012) Protein aggregates in Huntington's disease. Exp. Neurol. 238, 1–11.
5. Aso E., Juves S., Maldonado R. and Ferrer I. (2013) CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in AbetaPP/PS1 mice. J. Alzheimer's Dis. 35, 847–858.
6. Aso E., Sanchez-Pla A., Vegas-Lozano E., Maldonado R. and Ferrer I. (2015) Cannabis-based medicine reduces multiple pathological processes in AbetaPP/PS1 mice. J. Alzheimer's Dis. 43, 977–991.
7. Aso E., Andres-Benito P., Carmona M., Maldonado R. and Ferrer I. (2016) Cannabinoid receptor 2 participates in amyloid-beta processing in a mouse model of Alzheimer's Disease but plays a minor role in the therapeutic properties of a cannabis-based medicine. J. Alzheimer's Dis. 51, 489–500.
8. Aureli C., Cassano T., Masci A. et al. (2014) 5-S-cysteinyldopamine neurotoxicity: influence on the expression of alpha-synuclein and ERp57 in cellular and animal models of Parkinson's disease. J. Neurosci. Res. 92, 347–358.
9. Austin S. A., Floden A. M., Murphy E. J. and Combs C. K. (2006) Alpha-synuclein expression modulates microglial activation phenotype. J. Neurosci. 26, 10558–10563.
10. Bachmeier C., Beaulieu-Abdelahad D., Mullan M. and Paris D. (2013) Role of the cannabinoid system in the transit of beta-amyloid across the blood-brain barrier. Mol. Cell Neurosci. 56, 255–262.
11. Bari M., Battista N., Valenza M. et al. (2013) In vitro and in vivo models of Huntington's disease show alterations in the endocannabinoid system. FEBS J. 280, 3376–3388.
12. Bartels A. L. and Leenders K. L. (2009) Parkinson's disease: the syndrome, the pathogenesis and pathophysiology. Cortex 45, 915–921.
13. Basavarajappa B. S. (2015) Fetal alcohol spectrum disorder: potential role of endocannabinoids signaling. Brain Sci. 5, 456–493.
14. Basavarajappa B. S. and Arancio O. (2008) Synaptic plasticity: emerging role for endocannabinoid system, in Synaptic Plasticity: New Research (Kaiser T. F. and Peters F. J., eds.), pp. 77–112. Nova Science Publishers Inc, New York, NY.
15. Basavarajappa B. S. and Subbanna S. (2014) CB1 receptor-mediated signaling underlies the hippocampal synaptic, learning and memory deficits following treatment with JWH-081, a new component of spice/K2 preparations. Hippocampus 24, 178–188.
16. Basavarajappa B. S., Saito M., Cooper T. B. and Hungund B. L. (2003) Chronic ethanol inhibits the anandamide transport and increases extracellular anandamide levels in cerebellar granule neurons. Eur. J. Pharmacol. 466, 73–83.
17. Battista N., Bari M., Tarditi A. et al. (2007) Severe deficiency of the fatty acid amide hydrolase (FAAH) activity segregates with the Huntington's disease mutation in peripheral lymphocytes. Neurobiol. Dis. 27, 108–116.
18. Beltramo M. and Piomelli D. (2000) Carrier-mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2-arachidonylglycerol. NeuroReport 11, 1231–1235.
19. Beltramo M., Stella N., Calignano A., Lin S. Y., Makriyannis A. and Piomelli D. (1997) Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277, 1094–1097.
20. Benito C., Nunez E., Tolon R. M., Carrier E. J., Rabano A., Hillard C. J. and Romero J. (2003) Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J. Neurosci. 23, 11136–11141.
21. Berghuis P., Rajnicek A. M., Morozov Y. M. et al. (2007) Hardwiring the brain: endocannabinoids shape neuronal connectivity. Science 316, 1212–1216.
22. Biegon A. and Kerman I. A. (2001) Autoradiographic study of pre- and postnatal distribution of cannabinoid receptors in human brain. NeuroImage 14, 1463–1468.
23. Bisogno T., Berrendero F., Ambrosino G., Cebeira M., Ramos J. A., Fernandez-Ruiz J. J. and Di Marzo V. (1999a) Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. Biochem. Biophys. Res. Commun. 256, 377–380.
24. Bisogno T., Melck D., De Petrocellis L. and Di Marzo V. (1999b) Phosphatidic acid as the biosynthetic precursor of the endocannabinoid 2-arachidonoylglycerol in intact mouse neuroblastoma cells stimulated with ionomycin. J. Neurochem. 72, 2113–2119.
25. Bisogno T., MacCarrone M., De Petrocellis L., Jarrahian A., Finazzi-Agro A., Hillard C. and Di Marzo V. (2001) The uptake by cells of 2-arachidonoylglycerol, an endogenous agonist of cannabinoid receptors. Eur. J. Biochem. 268, 1982–1989.
26. Bisogno T., Martire A., Petrosino S., Popoli P. and Di Marzo V. (2008) Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington's disease. Neurochem. Int. 52, 307–313.
27. Blazquez C., Chiarlone A., Sagredo O. et al. (2011) Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. Brain 134, 119–136.
28. Bouaboula M., Poinot-Chazel C., Marchand J., Canat X., Bourrie B., Rinaldi-Carmona M., Calandra B., Le Fur G. and Casellas P. (1996) Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur. J. Biochem. 237, 704–711.
29. Branchi I., D'Andrea I., Armida M., Cassano T., Pezzola A., Potenza R. L., Morgese M. G., Popoli P. and Alleva E. (2008) Nonmotor symptoms in Parkinson's disease: investigating early-phase onset of behavioral dysfunction in the 6-hydroxydopamine-lesioned rat model. J. Neurosci. Res. 86, 2050–2061.
30. Branchi I., D'Andrea I., Armida M. et al. (2010) Striatal 6-OHDA lesion in mice: investigating early neurochemical changes underlying Parkinson's disease. Behav. Brain Res. 208, 137–143.
31. Breivogel C. S. and Childers S. R. (2000) Cannabinoid agonist signal transduction in rat brain: comparison of cannabinoid agonists in receptor binding, G-protein activation, and adenylyl cyclase inhibition. J. Pharmacol. Exp. Ther. 295, 328–336.
32. Brenneisen R. (2007) Chemistry and analysis of phytocannabinoids and other Cannabis constituents. in In Marijuana and the Cannabinoids (ElSohly M. A., ed.), pp. 17–49. Humana Press, Totowa, NJ.
33. Browne S. E., Ferrante R. J. and Beal M. F. (1999) Oxidative stress in Huntington's disease. Brain Pathol. 9, 147–163.
34. Buckley N. E., Hansson S., Harta G. and Mezey E. (1998) Expression of the CB1 and CB2 receptor messenger RNAs during embryonic development in the rat. Neuroscience 82, 1131–1149.
35. Calne D., Schulzer M., Mak E. and Stoessl A. J. (2005) Treatment for the progression of Parkinson's disease. Lancet Neurol. 4, 206.
36. Campion D., Dumanchin C., Hannequin D. et al. (1999) Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am. J. Hum. Genet. 65, 664–670.
37. Cao X., Liang L., Hadcock J. R., Iredale P. A., Griffith D. A., Menniti F. S., Factor S., Greenamyre J. T. and Papa S. M. (2007) Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys. J. Pharmacol. Exp. Ther. 323, 318–326.
38. Cao C., Li Y., Liu H., Bai G., Mayl J., Lin X., Sutherland K., Nabar N. and Cai J. (2014) The potential therapeutic effects of THC on Alzheimer's disease. J. Alzheimer's Dis. 42, 973–984.
39. Carnevale D., Perrotta M., Lembo G. and Trimarco B. (2016) Pathophysiological links among hypertension and Alzheimer's Disease. High Blood Press. Cardiovasc. Prev. 23, 3–7.
40. Carracedo A., Gironella M., Lorente M., Garcia S., Guzman M., Velasco G. and Iovanna J. L. (2006a) Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Res. 66, 6748–6755.
41. Carracedo A., Lorente M., Egia A. et al. (2006b) The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. Cancer Cell 9, 301–312.
42. Carrier E. J., Kearn C. S., Barkmeier A. J., Breese N. M., Yang W., Nithipatikom K., Pfister S. L., Campbell W. B. and Hillard C. J. (2004) Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. Mol. Pharmacol. 65, 999–1007.
43. Casarejos M. J., Perucho J., Gomez A. et al. (2013) Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy. J. Alzheimer's Dis. 35, 525–539.
44. Caulfield M. P. and Brown D. A. (1992) Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. Br. J. Pharmacol. 106, 231–232.
45. Celorrio M., Fernandez-Suarez D., Rojo-Bustamante E. et al. (2016) Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease. Brain Behav. Immun. 57, 94–105.
46. Centonze D., Rossi S., Prosperetti C., Tscherter A., Bernardi G., Maccarrone M. and Calabresi P. (2005) Abnormal sensitivity to cannabinoid receptor stimulation might contribute to altered gamma-aminobutyric acid transmission in the striatum of R6/2 Huntington's disease mice. Biol. Psychiatry 57, 1583–1589.
47. Cerri S., Levandis G., Ambrosi G. et al. (2014) Neuroprotective potential of adenosine A2A and cannabinoid CB1 receptor antagonists in an animal model of Parkinson disease. J. Neuropathol. Exp. Neurol. 73, 414–424.
48. Chen X., Zhang J. and Chen C. (2011) Endocannabinoid 2-arachidonoylglycerol protects neurons against beta-amyloid insults. Neuroscience 178, 159–168.
49. Chen R., Zhang J., Wu Y., Wang D., Feng G., Tang Y. P., Teng Z. and Chen C. (2012) Monoacylglycerol lipase is a therapeutic target for Alzheimer's disease. Cell Rep. 2, 1329–1339.
50. Childers S. R., Sexton T. and Roy M. B. (1994) Effects of anandamide on cannabinoid receptors in rat brain membranes. Biochem. Pharmacol. 47, 711–715.
51. Choi I. Y., Ju C., Anthony Jalin A. M., da Lee I., Prather P. L. and Kim W. K. (2013) Activation of cannabinoid CB2 receptor-mediated AMPK/CREB pathway reduces cerebral ischemic injury. Am. J. Pathol. 182, 928–939.
52. Chung Y. C., Bok E., Huh S. H. et al. (2011) Cannabinoid receptor type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation. J. Immunol. 187, 6508–6517.
53. Clifford D. B. (1983) Tetrahydrocannabinol for tremor in multiple sclerosis. Ann. Neurol. 13, 669–671.
54. Concannon R. M., Okine B. N., Finn D. P. and Dowd E. (2016) Upregulation of the cannabinoid CB2 receptor in environmental and viral inflammation-driven rat models of Parkinson's disease. Exp. Neurol. 283, 204–212.
55. Consroe P., Sandyk R. and Snider S. R. (1986) Open label evaluation of cannabidiol in dystonic movement disorders. Int. J. Neurosci. 30, 277–282.
56. Consroe P., Laguna J., Allender J., Snider S., Stern L., Sandyk R., Kennedy K. and Schram K. (1991) Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol. Biochem. Behav. 40, 701–708.
57. Consroe P., Musty R., Rein J., Tillery W. and Pertwee R. (1997) The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur. Neurol. 38, 44–48.
58. Currais A., Quehenberger O., Armando A. M., Daugherty D., Maher P. and Schubert D. (2016) Amyloid proteotoxicity initiates an inflammatory response blocked by cannabinoids. npj Aging Mech. Dis. 16012, 1–8.
59. Curtis A. and Rickards H. (2006) Nabilone could treat chorea and irritability in Huntington's disease. J. Neuropsychiatry Clin. Neurosci. 18, 553–554.
60. Curtis M. A., Faull R. L. and Glass M. (2006) A novel population of progenitor cells expressing cannabinoid receptors in the subependymal layer of the adult normal and Huntington's disease human brain. J. Chem. Neuroanat. 31, 210–215.
61. Curtis A., Mitchell I., Patel S., Ives N. and Rickards H. (2009) A pilot study using nabilone for symptomatic treatment in Huntington's disease. Mov. Disord. 24, 2254–2259.
62. D'Addario C., Di Francesco A., Arosio B. et al. (2012) Epigenetic regulation of fatty acid amide hydrolase in Alzheimer disease. PLoS ONE 7, e39186.
63. Day T. A., Rakhshan F., Deutsch D. G. and Barker E. L. (2001) Role of fatty acid amide hydrolase in the transport of the endogenous cannabinoid anandamide. Mol. Pharmacol. 59, 1369–1375.
64. Denora N., Cassano T., Laquintana V., Lopalco A., Trapani A., Cimmino C. S., Laconca L., Giuffrida A. and Trapani G. (2012) Novel codrugs with GABAergic activity for dopamine delivery in the brain. Int. J. Pharm. 437, 221–231.
65. Denovan-Wright E. M. and Robertson H. A. (2000) Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice. Neuroscience 98, 705–713.
66. Derkinderen P., Valjent E., Toutant M., Corvol J. C., Enslen H., Ledent C., Trzaskos J., Caboche J. and Girault J. A. (2003) Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. J. Neurosci. 23, 2371–2382.
67. Deutsch D. G., Glaser S. T., Howell J. M., Kunz J. S., Puffenbarger R. A., Hillard C. J. and Abumrad N. (2001) The cellular uptake of anandamide is coupled to its breakdown by fatty-acid amide hydrolase. J. Biol. Chem. 276, 6967–6973.
68. Devane W. A. and Axelrod J. (1994) Enzymatic synthesis of anandamide, an endogenous ligand for the cannabinoid receptor, by brain membranes. Proc. Natl Acad. Sci. USA 91, 6698–6701.
69. Dewey W. L. (1986) Cannabinoid pharmacology. Pharmacol. Rev. 38, 151–178.
70. Di Gioia S., Trapani A., Mandracchia D. et al. (2015) Intranasal delivery of dopamine to the striatum using glycol chitosan/sulfobutylether-beta-cyclodextrin based nanoparticles. Eur. J. Pharm. Biopharm. 94, 180–193.
71. Di Marzo V. (1998) ‘Endocannabinoids’ and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible. Biochim. Biophys. Acta 1392, 153–175.
72. Di Marzo V., Fontana A., Cadas H., Schinelli S., Cimino G., Schwartz J. C. and Piomelli D. (1994) Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372, 686–691.
73. Di Marzo V., Hill M. P., Bisogno T., Crossman A. R. and Brotchie J. M. (2000) Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J. 14, 1432–1438.
74. Diaz-Alonso J., Paraiso-Luna J., Navarrete C. et al. (2016) VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington's disease. Sci. Rep., 6, 29789.
75. Dowie M. J., Bradshaw H. B., Howard M. L., Nicholson L. F., Faull R. L., Hannan A. J. and Glass M. (2009) Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease. Neuroscience 163, 456–465.
76. Ehrhart J., Obregon D., Mori T. et al. (2005) Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J. Neuroinflammation 2, 29.
77. El-Banoua F., Caraballo I., Flores J. A., Galan-Rodriguez B. and Fernandez-Espejo E. (2004) Effects on turning of microinjections into basal ganglia of D(1) and D(2) dopamine receptors agonists and the cannabinoid CB(1) antagonist SR141716A in a rat Parkinson's model. Neurobiol. Dis. 16, 377–385.
78. Esposito G., De Filippis D., Steardo L., Scuderi C., Savani C., Cuomo V. and Iuvone T. (2006) CB1 receptor selective activation inhibits beta-amyloid-induced iNOS protein expression in C6 cells and subsequently blunts tau protein hyperphosphorylation in co-cultured neurons. Neurosci. Lett. 404, 342–346.
79. Esposito G., Iuvone T., Savani C., Scuderi C., De Filippis D., Papa M., Di Marzo V. and Steardo L. (2007) Opposing control of cannabinoid receptor stimulation on amyloid-beta-induced reactive gliosis: in vitro and in vivo evidence. J. Pharmacol. Exp. Ther. 322, 1144–1152.
80. Eubanks L. M., Rogers C. J., Beuscher A. E., IV, Koob G. F., Olson A. J., Dickerson T. J. and Janda K. D. (2006) A Molecular link between the active component of Marijuana and Alzheimer's Disease pathology. Mol. Pharm. 3, 773–777.
81. Fakhfouri G., Ahmadiani A., Rahimian R., Grolla A. A., Moradi F. and Haeri A. (2012) WIN55212-2 attenuates amyloid-beta-induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR-gamma pathway. Neuropharmacology 63, 653–666.
82. Farooqui A. A., Liss L. and Horrocks L. A. (1988) Neurochemical aspects of Alzheimer's disease: involvement of membrane phospholipids. Metab. Brain Dis. 3, 19–35.
83. Fernandez-Espejo E., Caraballo I., de Fonseca F. R., El Banoua F., Ferrer B., Flores J. A. and Galan-Rodriguez B. (2005) Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism. Neurobiol. Dis. 18, 591–601.
84. Fernandez-Ruiz J., Romero J., Velasco G., Tolon R. M., Ramos J. A. and Guzman M. (2007) Cannabinoid CB2 receptor: a new target for controlling neural cell survival? Trends Pharmacol. Sci. 28, 39–45.
85. Fernandez-Ruiz J., Pazos M. R., Garcia-Arencibia M., Sagredo O. and Ramos J. A. (2008) Role of CB2 receptors in neuroprotective effects of cannabinoids. Mol. Cell. Endocrinol. 286, S91–S96.
86. Ferrer B., Asbrock N., Kathuria S., Piomelli D. and Giuffrida A. (2003) Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias. Eur. J. Neurosci. 18, 1607–1614.
87. Freund T. F., Katona I. and Piomelli D. (2003) Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev. 83, 1017–1066.
88. Gajardo-Gomez R., Labra V. C., Maturana C. J., Shoji K. F., Santibanez C. A., Saez J. C., Giaume C. and Orellana J. A. (2017) Cannabinoids prevent the amyloid beta-induced activation of astroglial hemichannels: a neuroprotective mechanism. Glia 65, 122–137.
89. Gao H. M., Kotzbauer P. T., Uryu K., Leight S., Trojanowski J. Q. and Lee V. M. (2008) Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J. Neurosci. 28, 7687–7698.
90. Gapen P. (1982) THC or analogues may alleviate some tremors. JAMA 248, 2215.
91. Garcia C., Palomo-Garo C., Garcia-Arencibia M., Ramos J., Pertwee R. and Fernandez-Ruiz J. (2011) Symptom-relieving and neuroprotective effects of the phytocannabinoid Delta(9)-THCV in animal models of Parkinson's disease. Br. J. Pharmacol. 163, 1495–1506.
92. Garcia-Arencibia M., Gonzalez S., de Lago E., Ramos J. A., Mechoulam R. and Fernandez-Ruiz J. (2007) Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties. Brain Res. 1134, 162–170.
93. Garcia-Arencibia M., Garcia C., Kurz A., Rodriguez-Navarro J. A., Gispert-Sachez S., Mena M. A., Auburger G., deYebenes J. G. and Fernandez-Ruiz J. (2009) Cannabinoid CB1 receptors are early downregulated followed by a further upregulation in the basal ganglia of mice with deletion of specific park genes. J. Neural. Transm., 73, 269–275.
94. Garcia-Gutierrez M. S., Ortega-Alvaro A., Busquets-Garcia A., Perez-Ortiz J. M., Caltana L., Ricatti M. J., Brusco A., Maldonado R. and Manzanares J. (2013) Synaptic plasticity alterations associated with memory impairment induced by deletion of CB2 cannabinoid receptors. Neuropharmacology 73, 388–396.
95. Gerhard A., Pavese N., Hotton G. et al. (2006) In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol. Dis. 21, 404–412.
96. Gertsch J., Schoop R., Kuenzle U. and Suter A. (2004) Echinacea alkylamides modulate TNF-alpha gene expression via cannabinoid receptor CB2 and multiple signal transduction pathways. FEBS Lett. 577, 563–569.
97. Giuffrida A., Beltramo M. and Piomelli D. (2001) Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. J. Pharmacol. Exp. Ther. 298, 7–14.
98. Glaser S. T., Abumrad N. A., Fatade F., Kaczocha M., Studholme K. M. and Deutsch D. G. (2003) Evidence against the presence of an anandamide transporter. Proc. Natl Acad. Sci. USA 100, 4269–4274.
99. Glass M., Faull R. L. and Dragunow M. (1993) Loss of cannabinoid receptors in the substantia nigra in Huntington's disease. Neuroscience 56, 523–527.
100. Glass M., Dragunow M. and Faull R. L. (1997) Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 77, 299–318.
101. Glass M., Dragunow M. and Faull R. L. (2000) The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 97, 505–519.
102. Gomez-Galvez Y., Palomo-Garo C., Fernandez-Ruiz J. and Garcia C. (2016) Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson's disease. Prog. Neuropsychopharmacol. Bol. Psychiatry 64, 200–208.
103. Gonzalez S., Scorticati C., Garcia-Arencibia M., de Miguel R., Ramos J. A. and Fernandez-Ruiz J. (2006) Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease. Brain Res. 1073–1074, 209–219.
104. Graham E. S., Ball N., Scotter E. L., Narayan P., Dragunow M. and Glass M. (2006) Induction of Krox-24 by endogenous cannabinoid type 1 receptors in Neuro2A cells is mediated by the MEK-ERK MAPK pathway and is suppressed by the phosphatidylinositol 3-kinase pathway. J. Biol. Chem. 281, 29085–29095.
105. Grammas P. (2011) Neurovascular dysfunction, inflammation and endothelial activation: implications for the pathogenesis of Alzheimer's disease. J. Neuroinflammation 8, 26.
106. Gubellini P., Picconi B., Bari M., Battista N., Calabresi P., Centonze D., Bernardi G., Finazzi-Agro A. and Maccarrone M. (2002) Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J. Neurosci. 22, 6900–6907.
107. Hamel E., Royea J., Ongali B. and Tong X. K. (2016) Neurovascular and cognitive failure in Alzheimer's Disease: benefits of cardiovascular therapy. Cell. Mol. Neurobiol. 36, 219–232.
108. Hansen H. H., Hansen S. H., Schousboe A. and Hansen H. S. (2000) Determination of the phospholipid precursor of anandamide and other N-acylethanolamine phospholipids before and after sodium azide-induced toxicity in cultured neocortical neurons. J. Neurochem. 75, 861–871.
109. Hardy J. (1996a) Molecular genetics of Alzheimer's disease. Acta Neurol. Scand. Suppl. 165, 13–17.
110. Hardy J. (1996b) New insights into the genetics of Alzheimer's disease. Ann. Med. 28, 255–258.
111. Hardy J. and Selkoe D. J. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353–356.
112. Harkany T., Mackie K. and Doherty P. (2008) Wiring and firing neuronal networks: endocannabinoids take center stage. Curr. Opin. Neurobiol. 18, 338–345.
113. Herkenham M., Lynn A. B., de Costa B. R. and Richfield E. K. (1991) Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res. 547, 267–274.
114. Herrera B., Carracedo A., Diez-Zaera M., Guzman M. and Velasco G. (2005) p38 MAPK is involved in CB2 receptor-induced apoptosis of human leukaemia cells. FEBS Lett. 579, 5084–5088.
115. Hickey M. A. and Chesselet M. F. (2003) Apoptosis in Huntington's disease. Prog. Neuropsychopharmacol. Bol. Psychiatry 27, 255–265.
116. Hillard C. J. and Jarrahian A. (2000) The movement of N-arachidonoylethanolamine (anandamide) across cellular membranes. Chem. Phys. Lipids 108, 123–134.
117. Hillard C. J., Edgemond W. S., Jarrahian A. and Campbell W. B. (1997) Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. J. Neurochem. 69, 631–638.
118. Hollister L. E. (1986) Health aspects of cannabis. Pharmacol. Rev. 38, 1–20.
119. Howlett A. C. (1995) Pharmacology of cannabinoid receptors. Annu. Rev. Pharmacol. Toxicol. 35, 607–634.
120. Howlett A. C. (2002) The cannabinoid receptors. Prostaglandins Other Lipid Mediat. 68–69, 619–631.
121. Howlett A. C. and Mukhopadhyay S. (2000) Cellular signal transduction by anandamide and 2-arachidonoylglycerol. Chem. Phys. Lipids 108, 53–70.
122. Howlett A. C., Bidaut-Russell M., Devane W. A., Melvin L. S., Johnson M. R. and Herkenham M. (1990) The cannabinoid receptor: biochemical, anatomical and behavioral characterization. Trends Neurosci. 13, 420–423.
123. Howlett A. C., Barth F., Bonner T. I. et al. (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54, 161–202.
124. Hurley M. J., Mash D. C. and Jenner P. (2003) Expression of cannabinoid CB1 receptor mRNA in basal ganglia of normal and parkinsonian human brain. J. Neural. Transm. 110, 1279–1288.
125. Iuvone T., Esposito G., Esposito R., Santamaria R., Di Rosa M. and Izzo A. A. (2004) Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. J. Neurochem. 89, 134–141.
126. Janefjord E., Maag J. L., Harvey B. S. and Smid S. D. (2014) Cannabinoid effects on beta amyloid fibril and aggregate formation, neuronal and microglial-activated neurotoxicity in vitro. Cell. Mol. Neurobiol. 34, 31–42.
127. Javed H., Azimullah S., Haque M. E. and Ojha S. K. (2016) Cannabinoid type 2 (CB2) receptors activation protects against oxidative stress and neuroinflammation associated dopaminergic neurodegeneration in rotenone model of Parkinson's disease. Front. Neurosci. 10, 321.
128. Jayant S., Sharma B. M., Bansal R. and Sharma B. (2016) Pharmacological benefits of selective modulation of cannabinoid receptor type 2 (CB2) in experimental Alzheimer's disease. Pharmacol. Biochem. Behav. 140, 39–50.
129. Katona I., Sperlagh B., Sik A., Kafalvi A., Vizi E. S., Mackie K. and Freund T. F. (1999) Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J. Neurosci. 19, 4544–4558.
130. Katona I., Rancz E. A., Acsady L., Ledent C., Mackie K., Hajos N. and Freund T. F. (2001) Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. J. Neurosci. 21, 9506–9518.
131. Katona I., Urban G. M., Wallace M., Ledent C., Jung K. M., Piomelli D., Mackie K. and Freund T. F. (2006) Molecular composition of the endocannabinoid system at glutamatergic synapses. J. Neurosci. 26, 5628–5637.
132. Kelsey J. E., Harris O. and Cassin J. (2009) The CB(1) antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease. Behav. Brain Res. 203, 304–307.
133. Klegeris A., Bissonnette C. J. and McGeer P. L. (2003) Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. Br. J. Pharmacol. 139, 775–786.
134. Klegeris A., Pelech S., Giasson B. I., Maguire J., Zhang H., McGeer E. G. and McGeer P. L. (2008) Alpha-synuclein activates stress signaling protein kinases in THP-1 cells and microglia. Neurobiol. Aging 29, 739–752.
135. Kofalvi A., Lemos C., Martin-Moreno A. M. et al. (2016) Stimulation of brain glucose uptake by cannabinoid CB2 receptors and its therapeutic potential in Alzheimer's disease. Neuropharmacology 110, 519–529.
136. Koppel J., Vingtdeux V., Marambaud P., d'Abramo C., Jimenez H., Stauber M., Friedman R. and Davies P. (2014) CB2 receptor deficiency increases amyloid pathology and alters tau processing in a transgenic mouse model of Alzheimer's disease. Mol. Med. 20, 29–36.
137. Kreitzer A. C. and Malenka R. C. (2007) Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature 445, 643–647.
138. Kruger R., Kuhn W., Muller T. et al. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18, 106–108.
139. de Lago E., de Miguel R., Lastres-Becker I., Ramos J. A. and Fernandez-Ruiz J. (2004) Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence. Brain Res. 1007, 152–159.
140. Laprairie R. B., Bagher A. M., Kelly M. E. and Denovan-Wright E. M. (2016) Biased type 1 cannabinoid receptor signaling influences neuronal viability in a cell culture model of Huntington disease. Mol. Pharmacol. 89, 364–375.
141. Lastres-Becker I., Cebeira M., de Ceballos M. L., Zeng B. Y., Jenner P., Ramos J. A. and Fernandez-Ruiz J. J. (2001a) Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. Eur. J. Neurosci. 14, 1827–1832.
142. Lastres-Becker I., Fezza F., Cebeira M., Bisogno T., Ramos J. A., Milone A., Fernandez-Ruiz J. and Di Marzo V. (2001b) Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease. NeuroReport 12, 2125–2129.
143. Lastres-Becker I., Hansen H. H., Berrendero F., De Miguel R., Perez-Rosado A., Manzanares J., Ramos J. A. and Fernandez-Ruiz J. (2002) Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease. Synapse 44, 23–35.
144. Lastres-Becker I., Bizat N., Boyer F., Hantraye P., Brouillet E. and Fernandez-Ruiz J. (2003) Effects of cannabinoids in the rat model of Huntington's disease generated by an intrastriatal injection of malonate. NeuroReport 14, 813–816.
145. Lastres-Becker I., Bizat N., Boyer F., Hantraye P., Fernandez-Ruiz J. and Brouillet E. (2004) Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo. NeuroReport 15, 2375–2379.
146. Lastres-Becker I., Molina-Holgado F., Ramos J. A., Mechoulam R. and Fernandez-Ruiz J. (2005) Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol. Dis. 19, 96–107.
147. de Lau L. M. and Breteler M. M. (2006) Epidemiology of Parkinson's disease. Lancet Neurol. 5, 525–535.
148. Leung D., Saghatelian A., Simon G. M. and Cravatt B. F. (2006) Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids. Biochemistry 45, 4720–4726.
149. Li Y. and Kim J. (2016a) CB2 cannabinoid receptor knockout in mice impairs contextual long-term memory and enhances spatial working memory. Neural. Plast. 2016, 1–14.
150. Li Y. and Kim J. (2016b) Deletion of CB2 cannabinoid receptors reduces synaptic transmission and long-term potentiation in the mouse hippocampus. Hippocampus 26, 275–281.
151. Libro R., Diomede F., Scionti D., Piattelli A., Grassi G., Pollastro F., Bramanti P., Mazzon E. and Trubiani O. (2016) Cannabidiol modulates the expression of Alzheimer's disease-related genes in mesenchymal stem cells. Int. J. Mol. Sci. 18, 1–19.
152. Liu J., Wang L., Harvey-White J. et al. (2006) A biosynthetic pathway for anandamide. Proc. Natl Acad. Sci. USA 103, 13345–13350.
153. Liu J., Wang L., Harvey-White J. et al. (2008) Multiple pathways involved in the biosynthesis of anandamide. Neuropharmacology 54, 1–7.
154. Lopez-Sendon Moreno J. L., Garcia Caldentey J., Trigo Cubillo P. et al. (2016) A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease. J. Neurol. 263, 1390–1400.
155. Lu Y. and Anderson H. D. (2017) Cannabinoid signaling in health and disease. Can. J. Physiol. Pharmacol. 95, 311–327.
156. Maccarrone M., van der Stelt M., Rossi A., Veldink G. A., Vliegenthart J. F. and Agro A. F. (1998) Anandamide hydrolysis by human cells in culture and brain. J. Biol. Chem. 273, 32332–32339.
157. Maccarrone M., Gubellini P., Bari M., Picconi B., Battista N., Centonze D., Bernardi G., Finazzi-Agro A. and Calabresi P. (2003) Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism. J. Neurochem. 85, 1018–1025.
158. Mackie K. (2006) Mechanisms of CB1 receptor signaling: endocannabinoid modulation of synaptic strength. Int. J. Obes. (Lond) 30, S19–S23.
159. Mackie K. and Hille B. (1992) Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc. Natl Acad. Sci. USA 89, 3825–3829.
160. Mailleux P. and Vanderhaeghen J. J. (1992a) Age-related loss of cannabinoid receptor binding sites and mRNA in the rat striatum. Neurosci. Lett. 147, 179–181.
161. Mailleux P. and Vanderhaeghen J. J. (1992b) Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neurosci. 48, 655–668.
162. Maneuf Y. P., Nash J. E., Crossman A. R. and Brotchie J. M. (1996) Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus. Eur. J. Pharmacol. 308, 161–164.
163. Manuel I., Lombardero L., LaFerla F. M., Gimenez-Llort L. and Rodriguez-Puertas R. (2016) Activity of muscarinic, galanin and cannabinoid receptors in the prodromal and advanced stages in the triple transgenic mice model of Alzheimer's disease. Neuroscience 329, 284–293.
164. Maroof N., Ravipati S., Pardon M. C., Barrett D. A. and Kendall D. A. (2014) Reductions in endocannabinoid levels and enhanced coupling of cannabinoid receptors in the striatum are accompanied by cognitive impairments in the AbetaPPswe/PS1DeltaE9 mouse model of Alzheimer's disease. J. Alzheimer's Dis. 42, 227–245.
165. Martin-Moreno A. M., Reigada D., Ramirez B. G., Mechoulam R., Innamorato N., Cuadrado A. and de Ceballos M. L. (2011) Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease. Mol. Pharmacol. 79, 964–973.
166. Martin-Moreno A. M., Brera B., Spuch C. et al. (2012) Prolonged oral cannabinoid administration prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in Tg APP 2576 mice. J. Neuroinflammation 9, 8.
167. Maya-Lopez M., Colin-Gonzalez A. L., Aguilera G. et al. (2017) Neuroprotective effect of WIN55,212-2 against 3-nitropropionic acid-induced toxicity in the rat brain: involvement of CB1 and NMDA receptors. Am. J. Transl. Res. 9, 261–274.
168. Mazzola C., Micale V. and Drago F. (2003) Amnesia induced by beta-amyloid fragments is counteracted by cannabinoid CB1 receptor blockade. Eur. J. Pharmacol. 477, 219–225.
169. McCaw E. A., Hu H., Gomez G. T., Hebb A. L., Kelly M. E. and Denovan-Wright E. M. (2004) Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice. Eur. J. Biochem. 271, 4909–4920.
170. McGeer P. L., Itagaki S., Boyes B. E. and McGeer E. G. (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38, 1285–1291.
171. Mecha M., Feliu A., Carrillo-Salinas F. J., Rueda-Zubiaurre A., Ortega-Gutierrez S., de Sola R. G. and Guaza C. (2015) Endocannabinoids drive the acquisition of an alternative phenotype in microglia. Brain Behav. Immun. 49, 233–245.
172. Mechoulam R. and Parker L. A. (2013) The endocannabinoid system and the brain. Annu. Rev. Psychol. 64, 21–47.
173. Meschler J. P., Howlett A. C. and Madras B. K. (2001) Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates. Psychopharmacology 156, 79–85.
174. Micale V., Cristino L., Tamburella A., Petrosino S., Leggio G. M., Di Marzo V. and Drago F. (2010) Enhanced cognitive performance of dopamine D3 receptor “knock-out” mice in the step-through passive-avoidance test: assessing the role of the endocannabinoid/endovanilloid systems. Pharmacol. Res. 61, 531–536.
175. Mievis S., Blum D. and Ledent C. (2011) Worsening of Huntington disease phenotype in CB1 receptor knockout mice. Neurobiol. Dis. 42, 524–529.
176. Milton N. G. (2002) Anandamide and noladin ether prevent neurotoxicity of the human amyloid-beta peptide. Neurosci. Lett. 332, 127–130.
177. Molina-Holgado E., Vela J. M., Arevalo-Martin A., Almazan G., Molina-Holgado F., Borrell J. and Guaza C. (2002a) Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J. Neurosci. 22, 9742–9753.
178. Molina-Holgado F., Molina-Holgado E., Guaza C. and Rothwell N. J. (2002b) Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures. J. Neurosci. Res. 67, 829–836.
179. Molina-Holgado F., Pinteaux E., Moore J. D., Molina-Holgado E., Guaza C., Gibson R. M. and Rothwell N. J. (2003) Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. J. Neurosci. 23, 6470–6474.
180. Moreno E., Chiarlone A., Medrano M. et al. (2017) Singular location and signaling profile of adenosine A2A-cannabinoid CB1 receptor heteromers in the dorsal striatum. Neuropsychopharmacology doi: 10.1038/npp.2017.12. [Epub ahead of print].
181. Mounsey R. B., Mustafa S., Robinson L., Ross R. A., Riedel G., Pertwee R. G. and Teismann P. (2015) Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Exp. Neurol. 273, 36–44.
182. Mu J., Zhuang S. Y., Kirby M. T., Hampson R. E. and Deadwyler S. A. (1999) Cannabinoid receptors differentially modulate potassium A and D currents in hippocampal neurons in culture. J. Pharmacol. Exp. Ther. 291, 893–902.
183. Mulder J., Zilberter M., Pasquare S. J. et al. (2011) Molecular reorganization of endocannabinoid signalling in Alzheimer's disease. Brain 134, 1041–1060.
184. Muller-Vahl K. R., Kolbe H., Schneider U. and Emrich H. M. (1999a) Cannabis in movement disorders. Forsch. Komplementarmed. 6, 23–27.
185. Muller-Vahl K. R., Schneider U., Kolbe H. and Emrich H. M. (1999b) Treatment of Tourette's syndrome with delta-9-tetrahydrocannabinol. Am. J. Psychiat. 156, 495.
186. Müller-Vahl K., Schneider U. and Emrich H. (1999) Nabilone increases choreatic movements in Huntington's disease. Mov. Disord. 14, 1038–1040.
187. Nakane S., Oka S., Arai S., Waku K., Ishima Y., Tokumura A. and Sugiura T. (2002) 2-Arachidonoyl-sn-glycero-3-phosphate, an arachidonic acid-containing lysophosphatidic acid: occurrence and rapid enzymatic conversion to 2-arachidonoyl-sn-glycerol, a cannabinoid receptor ligand, in rat brain. Arch. Biochem. Biophys. 402, 51–58.
188. Natarajan V., Reddy P. V., Schmid P. C. and Schmid H. H. (1981) On the biosynthesis and metabolism of N-acylethanolamine phospholipids in infarcted dog heart. Biochim. Biophys. Acta 664, 445–448.
189. Nogueron M. I., Porgilsson B., Schneider W. E., Stucky C. L. and Hillard C. J. (2001) Cannabinoid receptor agonists inhibit depolarization-induced calcium influx in cerebellar granule neurons. J. Neurochem. 79, 371–381.
190. Ohno-Shosaku T., Sawada S. and Yamamoto C. (1998) Properties of depolarization-induced suppression of inhibitory transmission in cultured rat hippocampal neurons. Pflugers Arch. 435, 273–279.
191. Ohno-Shosaku T., Sawada S. and Kano M. (2000) Heterosynaptic expression of depolarization-induced suppression of inhibition (DSI) in rat hippocampal cultures. Neurosci. Res. 36, 67–71.
192. Ohno-Shosaku T., Maejima T. and Kano M. (2001) Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminal. Neuron 29, 729–738.
193. Ohno-Shosaku T., Tsubokawa H., Mizushima I., Yoneda N., Zimmer A. and Kano M. (2002) Presynaptic cannabinoid sensitivity is a major determinant of depolarization-induced retrograde suppression at hippocampal synapses. J. Neurosci. 22, 3864–3872.
194. Onaivi E. S., Ishiguro H., Gong J. P. et al. (2006) Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann. N. Y. Acad. Sci. 1074, 514–536.
195. Orihuela R., McPherson C. A. and Harry G. J. (2016) Microglial M1/M2 polarization and metabolic states. Br. J. Pharmacol. 173, 649–665.
196. Ouchi Y., Yoshikawa E., Sekine Y., Futatsubashi M., Kanno T., Ogusu T. and Torizuka T. (2005) Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann. Neurol. 57, 168–175.
197. Ozaita A., Puighermanal E. and Maldonado R. (2007) Regulation of PI3K/Akt/GSK-3 pathway by cannabinoids in the brain. J. Neurochem. 102, 1105–1114.
198. Palazuelos J., Aguado T., Egia A., Mechoulam R., Guzman M. and Galve-Roperh I. (2006) Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation. FASEB J. 20, 2405–2407.
199. Palazuelos J., Aguado T., Pazos M. R. et al. (2009) Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain 132, 3152–3164.
200. Palomo-Garo C., Gomez-Galvez Y., Garcia C. and Fernandez-Ruiz J. (2016) Targeting the cannabinoid CB2 receptor to attenuate the progression of motor deficits in LRRK2-transgenic mice. Pharmacol. Res. 110, 181–192.
201. Pan X., Ikeda S. R. and Lewis D. L. (1996) Rat brain cannabinoid receptor modulates N-type Ca2 + channels in a neuronal expression system. Mol. Pharmacol. 49, 707–714.
202. Pascual A. C., Martin-Moreno A. M., Giusto N. M., de Ceballos M. L. and Pasquare S. J. (2014) Normal aging in rats and pathological aging in human Alzheimer's disease decrease FAAH activity: modulation by cannabinoid agonists. Exp. Gerontol. 60, 92–99.
203. Passmore M. J. (2008) The cannabinoid receptor agonist nabilone for the treatment of dementia-related agitation. Int. J. Geriatr. Psychiatry 23, 116–117.
204. Pertwee R. G. (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther. 74, 129–180.
205. Pinto J. C., Potie F., Rice K. C., Boring D., Johnson M. R., Evans D. M., Wilken G. H., Cantrell C. H. and Howlett A. C. (1994) Cannabinoid receptor binding and agonist activity of amides and esters of arachidonic acid. Mol. Pharmacol. 46, 516–522.
206. Pintor A., Tebano M. T., Martire A. et al. (2006) The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum. Neuropharmacology 51, 1004–1012.
207. Pisani A., Fezza F., Galati S. et al. (2005) High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients. Ann. Neurol. 57, 777–779.
208. Polymeropoulos M. H., Lavedan C., Leroy E. et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045–2047.
209. Prescott S. M. and Majerus P. W. (1983) Characterization of 1,2-diacylglycerol hydrolysis in human platelets. Demonstration of an arachidonoyl-monoacylglycerol intermediate. J. Biol. Chem. 258, 764–769.
210. Price D. A., Martinez A. A., Seillier A. et al. (2009) WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Eur. J. Neurosci. 29, 2177–2186.
211. Quintanilla R. A. and Johnson G. V. (2009) Role of mitochondrial dysfunction in the pathogenesis of Huntington's disease. Brain Res. Bull. 80, 242–247.
212. Ramirez B. G., Blazquez C., Gomez del Pulgar T., Guzman M. and de Ceballos M. L. (2005) Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J. Neurosci. 25, 1904–1913.
213. Reynolds A. D., Glanzer J. G., Kadiu I. et al. (2008a) Nitrated alpha-synuclein-activated microglial profiling for Parkinson's disease. J. Neurochem. 104, 1504–1525.
214. Reynolds A. D., Kadiu I., Garg S. K., Glanzer J. G., Nordgren T., Ciborowski P., Banerjee R. and Gendelman H. E. (2008b) Nitrated alpha-synuclein and microglial neuroregulatory activities. J. Neuroimmune Pharmacol. 3, 59–74.
215. Richfield E. K. and Herkenham M. (1994) Selective vulnerability in Huntington's disease: preferential loss of cannabinoid receptors in lateral globus pallidus. Ann. Neurol. 36, 577–584.
216. Rikani A. A., Choudhry Z., Choudhry A. M., Rizvi N., Ikram H., Mobassarah N. J. and Tulli S. (2014) The mechanism of degeneration of striatal neuronal subtypes in Huntington disease. Ann. Neurosci. 21, 112–114.
217. Romero J., Berrendero F., Garcia-Gil L., de la Cruz P., Ramos J. A. and Fernandez-Ruiz J. J. (1998) Loss of cannabinoid receptor binding and messenger RNA levels and cannabinoid agonist-stimulated [35S]guanylyl-5′O-(thio)-triphosphate binding in the basal ganglia of aged rats. Neuroscience 84, 1075–1083.
218. Sagredo O., Ramos J. A., Decio A., Mechoulam R. and Fernandez-Ruiz J. (2007) Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors. Eur. J. Neurosci. 26, 843–851.
219. Sagredo O., Gonzalez S., Aroyo I. et al. (2009) Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease. Glia 57, 1154–1167.
220. Samson M. T., Small-Howard A., Shimoda L. M., Koblan-Huberson M., Stokes A. J. and Turner H. (2003) Differential roles of CB1 and CB2 cannabinoid receptors in mast cells. J. Immunol. 170, 4953–4962.
221. Sandyk R., Snider S. R., Consroe P. and Elias S. M. (1986) Cannabidiol in dystonic movement disorders. Psychiatry Res. 18, 291.
222. Schmid P. C., Reddy P. V., Natarajan V. and Schmid H. H. (1983) Metabolism of N-acylethanolamine phospholipids by a mammalian phosphodiesterase of the phospholipase D type. J. Biol. Chem. 258, 9302–9306.
223. Schmole A. C., Lundt R., Ternes S. et al. (2015) Cannabinoid receptor 2 deficiency results in reduced neuroinflammation in an Alzheimer's disease mouse model. Neurobiol. Aging 36, 710–719.
224. Shibata M., Yamada S., Kumar S. R. et al. (2000) Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 106, 1489–1499.
225. Sieradzan K., Fox S., Dick J. and Brotchie J. (1998) The effects of the cannabinoid receptor agonist nabilone on l-DOPA induced dyskinesia in patients with idiopathic Parkinson's disease (PD). Mov. Disord. 13, 29.
226. Silverdale M. A., McGuire S., McInnes A., Crossman A. R. and Brotchie J. M. (2001) Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease. Exp. Neurol. 169, 400–406.
227. Simon G. M. and Cravatt B. F. (2008) Anandamide biosynthesis catalyzed by the phosphodiesterase GDE1 and detection of glycerophospho-N-acyl ethanolamine precursors in mouse brain. J. Biol. Chem. 283, 9341–9349.
228. Solas M., Francis P. T., Franco R. and Ramirez M. J. (2013) CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients. Neurobiol. Aging 34, 805–808.
229. van der Stelt M., Fox S. H., Hill M., Crossman A. R., Petrosino S., Di Marzo V. and Brotchie J. M. (2005) A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. FASEB J. 19, 1140–1142.
230. van der Stelt M., Mazzola C., Esposito G. et al. (2006) Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels. Cell. Mol. Life Sci. 63, 1410–1424.
231. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., Yamashita A. and Waku K. (1995) 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215, 89–97.
232. Sugiura T., Kobayashi Y., Oka S. and Waku K. (2002) Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. Prostaglandins Leukot. Essent. Fatty Acids 66, 173–192.
233. Sugiura T., Kishimoto S., Oka S. and Gokoh M. (2006) Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Prog. Lipid Res. 45, 405–446.
234. Sun Y. X., Tsuboi K., Okamoto Y., Tonai T., Murakami M., Kudo I. and Ueda N. (2004) Biosynthesis of anandamide and N-palmitoylethanolamine by sequential actions of phospholipase A2 and lysophospholipase D. Biochem. J. 380, 749–756.
235. Tadaiesky M. T., Dombrowski P. A., Da Cunha C. and Takahashi R. N. (2010) Effects of SR141716A on cognitive and depression-related behavior in an animal model of premotor Parkinson's Disease. Parkinsons Dis. 2010, 238491.
236. Tai Y. F., Pavese N., Gerhard A., Tabrizi S. J., Barker R. A., Brooks D. J. and Piccini P. (2007) Microglial activation in presymptomatic Huntington's disease gene carriers. Brain 130, 1759–1766.
237. Tanveer R., Gowran A., Noonan J., Keating S. E., Bowie A. G. and Campbell V. A. (2012) The endocannabinoid, anandamide, augments Notch-1 signaling in cultured cortical neurons exposed to amyloid-beta and in the cortex of aged rats. J. Biol. Chem. 287, 34709–34721.
238. Taylor J. M., Main B. S. and Crack P. J. (2013) Neuroinflammation and oxidative stress: co-conspirators in the pathology of Parkinson's disease. Neurochem. Int. 62, 803–819.
239. Ternianov A., Perez-Ortiz J. M., Solesio M. E., Garcia-Gutierrez M. S., Ortega-Alvaro A., Navarrete F., Leiva C., Galindo M. F. and Manzanares J. (2012) Overexpression of CB2 cannabinoid receptors results in neuroprotection against behavioral and neurochemical alterations induced by intracaudate administration of 6-hydroxydopamine. Neurobiol. Aging, 33, 421.e421–421.e416.
240. Thomas M. P., Chartrand K., Reynolds A., Vitvitsky V., Banerjee R. and Gendelman H. E. (2007) Ion channel blockade attenuates aggregated alpha synuclein induction of microglial reactive oxygen species: relevance for the pathogenesis of Parkinson's disease. J. Neurochem. 100, 503–519.
241. Tolon R. M., Nunez E., Pazos M. R., Benito C., Castillo A. I., Martinez-Orgado J. A. and Romero J. (2009) The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages. Brain Res. 1283, 148–154.
242. Trapani A., De Giglio E., Cafagna D., Denora N., Agrimi G., Cassano T., Gaetani S., Cuomo V. and Trapani G. (2011) Characterization and evaluation of chitosan nanoparticles for dopamine brain delivery. Int. J. Pharm. 419, 296–307.
243. Varvel S. A., Cravatt B. F., Engram A. E. and Lichtman A. H. (2006) Fatty acid amide hydrolase (-/-) mice exhibit an increased sensitivity to the disruptive effects of anandamide or oleamide in a working memory water maze task. J. Pharmacol. Exp. Ther. 317, 251–257.
244. Varvel S. A., Wise L. E., Niyuhire F., Cravatt B. F. and Lichtman A. H. (2007) Inhibition of fatty-acid amide hydrolase accelerates acquisition and extinction rates in a spatial memory task. Neuropsychopharmacology 32, 1032–1041.
245. Viveros-Paredes J. M., Gonzalez-Castañeda R. E., Escalante-Castañeda A., Tejeda-Martinez A. R., Castañeda-Achutigui F. and Flores-Soto M. E. (2017) Effect of inhibition of fatty acid amide hydrolase on MPTP-induced dopaminergic neuronal damage. Neurologia. doi: 10.1016/j.nrl.2016.11.008. [Epub ahead of print].
246. Volicer L., Stelly M., Morris J., McLaughlin J. and Volicer B. J. (1997) Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int. J. Geriatr. Psychiatry 12, 913–919.
247. Wilson R. I. and Nicoll R. A. (2001) Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 410, 588–592.
248. Wilson R. I. and Nicoll R. A. (2002) Endocannabinoid signaling in the brain. Science 296, 678–682.
249. Wilson R. I., Kunos G. and Nicoll R. A. (2001) Presynaptic specificity of endocannabinoid signaling in the hippocampus. Neuron 31, 453–462.
250. Wu J., Bie B., Yang H., Xu J. J., Brown D. L. and Naguib M. (2013) Activation of the CB2 receptor system reverses amyloid-induced memory deficiency. Neurobiol. Aging 34, 791–804.
251. Yan W., Yun Y., Ku T., Li G. and Sang N. (2016) NO2 inhalation promotes Alzheimer's disease-like progression: cyclooxygenase-2-derived prostaglandin E2 modulation and monoacylglycerol lipase inhibition-targeted medication. Sci. Rep. 6, 22429.
252. Zarranz J. J., Alegre J., Gomez-Esteban J. C. et al. (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55, 164–173.
253. Zeng B. Y., Dass B., Owen A., Rose S., Cannizzaro C., Tel B. C. and Jenner P. (1999) Chronic l-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats. Neurosci. Lett. 276, 71–74.
254. Zhang W., Wang T., Pei Z. et al. (2005) Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J. 19, 533–542.
255. Zhang J., Hu M., Teng Z., Tang Y. P. and Chen C. (2014) Synaptic and cognitive improvements by inhibition of 2-AG metabolism are through upregulation of microRNA-188-3p in a mouse model of Alzheimer's disease. J. Neurosci. 34, 14919–14933.